Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
- 20 May 2003
- journal article
- review article
- Published by Springer Nature in Gene Therapy
- Vol. 10 (11) , 955-963
- https://doi.org/10.1038/sj.gt.3302037
Abstract
Viral vectors have provided effective methods for in vivo gene delivery for therapeutic purposes. The ability of viruses to infect a wide variety of cell types in vivo has been exploited for several applications, such as liver, lung, muscle, brain, eye and many others. Immune responses directed towards the viral capsids and the transgene products have severely affected the ability of these vectors to induce long-term gene expression. This paper reviews the influence of viral vectors on antigen-presenting cells (APC), which are central to the induction of innate as well as adaptive immune responses. In this respect, we have focused on adenovirus and adeno-associated viruses because of the polar responses these vector systems induce in vivo. While adenovirus vector can induce significant inflammatory responses, adeno-associated viral vectors are characterized by their inability to consistantly induce immune responses to the transgene product. Understanding the mechanism of infection, transduction and activation of APC by viral vectors will provide strategies to develop safe vectors and prevent immune responses in gene therapies.Keywords
This publication has 84 references indexed in Scilit:
- Systemic Interleukin-6 Responses Following Administration of Adenovirus Gene Transfer Vectors to Humans by Different RoutesMolecular Therapy, 2002
- Adeno-Associated Virus Type 2-Mediated Transduction of Human Monocyte-Derived Dendritic Cells: Implications for Ex Vivo ImmunotherapyJournal of Virology, 2001
- Germline Incorporation of a Replication-Defective Adenoviral Vector in Mice Does Not Alter Immune Responses to Adenoviral VectorsMolecular Therapy, 2000
- Department of Health and Human Services: Recombinant DNA Advisory Committee National Institutes of HealthHuman Gene Therapy, 2000
- Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human TherapyHuman Gene Therapy, 2000
- An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and EpilepsyScience, 2000
- Additional Transduction Events after Subretinal Readministration of Recombinant Adeno-Associated VirusHuman Gene Therapy, 2000
- Induction of Immunity to Antigens Expressed by Recombinant Adeno-Associated Virus Depends on the Route of AdministrationClinical Immunology, 1999
- Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4IgGene Therapy, 1998
- Gene Transfer by Adeno-Associated Virus Vectors into the Central Nervous SystemExperimental Neurology, 1997